Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months

Follow-up of immunopathological and clinical effects

Research output: Article

15 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) is an autoimmune disease which involves the skin, as well as several internal organs. Most therapies available in this disease are symptomatic. Authors present a case of diffuse SSc with progressive disease not responding to currently available treatments. Therefore a 12-month protocol of repeated plasmapheresis and high-dose intravenous immunoglobulin treatment was administered with good clinical efficacy. Apart from monitoring the clinical symptoms throughout the treatment, authors also assessed a number of humoral and cellular immunolaboratory markers in order to obtain information on the immunomodulatory effects of this combined treatment in SSc.

Original languageEnglish
Pages (from-to)347-350
Number of pages4
JournalClinical Rheumatology
Volume28
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Plasmapheresis
Systemic Scleroderma
Intravenous Immunoglobulins
Therapeutics
Diffuse Scleroderma
Autoimmune Diseases
Skin

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{38d20589d06f44fb9659dee4ac005b1f,
title = "Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: Follow-up of immunopathological and clinical effects",
abstract = "Systemic sclerosis (SSc) is an autoimmune disease which involves the skin, as well as several internal organs. Most therapies available in this disease are symptomatic. Authors present a case of diffuse SSc with progressive disease not responding to currently available treatments. Therefore a 12-month protocol of repeated plasmapheresis and high-dose intravenous immunoglobulin treatment was administered with good clinical efficacy. Apart from monitoring the clinical symptoms throughout the treatment, authors also assessed a number of humoral and cellular immunolaboratory markers in order to obtain information on the immunomodulatory effects of this combined treatment in SSc.",
keywords = "Intravenous immunoglobulin, Plasmapheresis, Systemic sclerosis",
author = "Z. Szekanecz and M. Aleksza and P. Antal-Szalm{\'a}s and P. Solt{\'e}sz and K. Veres and S. Sz{\'a}nt{\'o} and Z. Szab{\'o} and A. V{\'e}gv{\'a}ri and Szilvia Szamosi and Gabriella Lakos and S. Sipka and G. Szegedi and John Varga and G. Szűcs",
year = "2009",
doi = "10.1007/s10067-008-1062-2",
language = "English",
volume = "28",
pages = "347--350",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months

T2 - Follow-up of immunopathological and clinical effects

AU - Szekanecz, Z.

AU - Aleksza, M.

AU - Antal-Szalmás, P.

AU - Soltész, P.

AU - Veres, K.

AU - Szántó, S.

AU - Szabó, Z.

AU - Végvári, A.

AU - Szamosi, Szilvia

AU - Lakos, Gabriella

AU - Sipka, S.

AU - Szegedi, G.

AU - Varga, John

AU - Szűcs, G.

PY - 2009

Y1 - 2009

N2 - Systemic sclerosis (SSc) is an autoimmune disease which involves the skin, as well as several internal organs. Most therapies available in this disease are symptomatic. Authors present a case of diffuse SSc with progressive disease not responding to currently available treatments. Therefore a 12-month protocol of repeated plasmapheresis and high-dose intravenous immunoglobulin treatment was administered with good clinical efficacy. Apart from monitoring the clinical symptoms throughout the treatment, authors also assessed a number of humoral and cellular immunolaboratory markers in order to obtain information on the immunomodulatory effects of this combined treatment in SSc.

AB - Systemic sclerosis (SSc) is an autoimmune disease which involves the skin, as well as several internal organs. Most therapies available in this disease are symptomatic. Authors present a case of diffuse SSc with progressive disease not responding to currently available treatments. Therefore a 12-month protocol of repeated plasmapheresis and high-dose intravenous immunoglobulin treatment was administered with good clinical efficacy. Apart from monitoring the clinical symptoms throughout the treatment, authors also assessed a number of humoral and cellular immunolaboratory markers in order to obtain information on the immunomodulatory effects of this combined treatment in SSc.

KW - Intravenous immunoglobulin

KW - Plasmapheresis

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=59749084203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59749084203&partnerID=8YFLogxK

U2 - 10.1007/s10067-008-1062-2

DO - 10.1007/s10067-008-1062-2

M3 - Article

VL - 28

SP - 347

EP - 350

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 3

ER -